egnite, Inc. Announces Data From Largest Contemporary Analysis of Valvular Heart Disease Prevalence in the United States
ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading-edge digital health company focused on providing artificial intelligence solutions to help hospitals identify and manage their most-at-risk cardiac patients, today announced new data that may help the clinical community better understand the impact of valvular heart disease (VHD) and the need for vigilance when screening and diagnosing patients. The results of the sponsored study, “Contemporary Prevalence of Valvular Heart Disease & Diagnostic Variability Across Centers”, were published in abstract form in the Journal of the American College of Cardiology (JACC) and will be presented at the 71st Annual Scientific Session of the American College of Cardiology (ACC.22) on April 3, 2022.
An analysis was performed on data from more than 714,000 patients (represented by more than 929,000 anonymized echocardiographic reports) at 35 community and university programs across the United States to assess the prevalence of aortic stenosis (AS), aortic regurgitation (AR), mitral stenosis (MS), mitral regurgitation (MR) and tricuspid regurgitation (TR). The data comes from the CardioCare platform, which includes a large data set of echocardiographic reports that can offer insights into the diagnosis and management of contemporary structural heart disease in real-world practice settings.
Main results demonstrated:
The prevalence of VHD continues to be significant and more frequent as patients age, with a notable increase beyond age 65. TR and MR were the most common types of VHD observed.
The prevalence of mixed VHD also increased with age; the combination of MR and TR was the most common form of mixed valve disease.
Overall, VHD of moderate or higher severity was found to be more common in female patients than in male patients.
Severe MR was more frequently diagnosed in centers offering catheter mitral valve repair technologies (1.2% versus 0.8%, p
“This is the first prevalence study from one of the world’s largest echo databases, highlighting the groundbreaking research potential of this formidable resource. Our work expands the sample size and generalizability of previous work by an order of magnitude in a large contemporary cohort,” said J. Matthew Brennan, MD, MPH, associate professor of medicine, interventional cardiology, Duke University School. of Medicine and lead author of the study. “These data confirm the increasing prevalence of single valve disease in elderly patients are the first large-scale findings to demonstrate an almost 1 in 20 prevalence of moderate or greater double valve disease, particularly MR/TR in elderly patients. elderly patients. This also suggests a greater prevalence of mitral and tricuspid disease in women with a greater prevalence of aortic stenosis in men.
VHD is a progressive and fatal disease that can occur when a heart valve is damaged or diseased. While prompt diagnosis is essential to ensure this patient population receives the treatment they need at the right time, the US healthcare system is fragmented, which can lead to delays in response that result in under-treatment or a lack of timely treatment.
“These data provide important contemporary insights into understanding the impact of valvular disease in the current era. Although we must continue to focus on improving outcomes for patients with aortic stenosis, the data underscores the urgent need for innovative therapies to treat patients with mitral regurgitation and tricuspid regurgitation as well as patients with valve disease. mixed,” said Glenn R. Barnhart, MD, egnite’s Chief Medical Officer. “This analysis represents egnite’s commitment to closing the gaps in patient care that prevent timely diagnosis and treatment. We are grateful to Dr. Brennan and the other study authors for leading this effort and making this analysis possible.
Time and place of presentation of the ACC:
Contemporary prevalence of valvular heart disease and diagnostic variability between centers
Featured by Lead Author James Thomas, MD, FASE, FA.CC, FESC, Center for Heart Valve Disease, Bluhm Cardiovascular Institute
Sunday, April 3, 2022, 11:45 a.m. ET
Poster Hall, Hall C in the Walter E. Washington Convention Center, Washington, DC
About Egnite, Inc.
egnite is an advanced technology digital health company, spun off from Edwards Lifesciences, focused on providing artificial intelligence solutions to help hospitals identify and manage their most-at-risk patients. The company is a market leader in structural heart solutions with a vision to improve outcomes for every structural heart patient in America. egnite’s flagship artificial intelligence platform, CardioCare, has partnered with more than 50 hospitals nationwide and leverages the program’s big data analytics platform of over one million patients. echocardiograms to raise the quality of patient care. The company is based in Aliso Viejo, California. For more information, visit www.egnitehealth.com.